AU2003250890B2 - Benzimidazole derivatives - Google Patents

Benzimidazole derivatives Download PDF

Info

Publication number
AU2003250890B2
AU2003250890B2 AU2003250890A AU2003250890A AU2003250890B2 AU 2003250890 B2 AU2003250890 B2 AU 2003250890B2 AU 2003250890 A AU2003250890 A AU 2003250890A AU 2003250890 A AU2003250890 A AU 2003250890A AU 2003250890 B2 AU2003250890 B2 AU 2003250890B2
Authority
AU
Australia
Prior art keywords
benzimidazol
phenyl
acetamide
chlorothiophen
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003250890A
Other languages
English (en)
Other versions
AU2003250890A1 (en
Inventor
Christopher Barnes
Bertram Cezanne
Dieter Dorsch
Johannes Gleitz
Werner Mederski
Christos Tsaklakidis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2003250890A1 publication Critical patent/AU2003250890A1/en
Application granted granted Critical
Publication of AU2003250890B2 publication Critical patent/AU2003250890B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2003250890A 2002-08-20 2003-07-04 Benzimidazole derivatives Ceased AU2003250890B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10238002.3 2002-08-20
DE10238002A DE10238002A1 (de) 2002-08-20 2002-08-20 Benzimidazolderivate
PCT/EP2003/007180 WO2004017963A1 (de) 2002-08-20 2003-07-04 Benzimidazolderivate

Publications (2)

Publication Number Publication Date
AU2003250890A1 AU2003250890A1 (en) 2004-03-11
AU2003250890B2 true AU2003250890B2 (en) 2009-07-16

Family

ID=31197107

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003250890A Ceased AU2003250890B2 (en) 2002-08-20 2003-07-04 Benzimidazole derivatives

Country Status (13)

Country Link
US (1) US7566789B2 (enExample)
EP (1) EP1558247B1 (enExample)
JP (1) JP4668614B2 (enExample)
CN (1) CN1674893A (enExample)
AR (1) AR041024A1 (enExample)
AT (1) ATE386518T1 (enExample)
AU (1) AU2003250890B2 (enExample)
BR (1) BR0313634A (enExample)
CA (1) CA2496139C (enExample)
DE (2) DE10238002A1 (enExample)
ES (1) ES2303606T3 (enExample)
RU (1) RU2005108042A (enExample)
WO (1) WO2004017963A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL401638A1 (pl) * 2002-03-13 2013-05-27 Array Biopharma Inc. N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
AU2003279735A1 (en) * 2002-10-02 2004-04-23 Bristol-Myers Squibb Company Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor xa inhibitors
EP1702919B1 (en) * 2003-12-29 2012-05-30 Msd K.K. Novel 2-heteroaryl-substituted benzimidazole derivative
US20060160799A1 (en) 2004-04-23 2006-07-20 Alekshun Michael N Transcription factor modulating compounds and methods of use thereof
TW200720255A (en) 2005-07-13 2007-06-01 Taiho Pharmaceutical Co Ltd Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
WO2007037534A1 (ja) 2005-09-30 2007-04-05 Banyu Pharmaceutical Co., Ltd. ２－へテロアリール置換インドール誘導体
US8410155B2 (en) 2006-12-15 2013-04-02 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIA inhibitors
AU2008335709A1 (en) * 2007-12-13 2009-06-18 Amgen Inc. Gamma secretase modulators
CA2722606A1 (en) * 2008-05-05 2009-11-12 Amgen Inc. Urea compounds as gamma secretase modulators
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
US8946426B2 (en) 2009-02-06 2015-02-03 Janssen Pharmaceuticals, Inc. Substituted bicyclic heterocyclic compounds as gamma secretase modulators
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
ES2431619T3 (es) 2009-05-07 2013-11-27 Janssen Pharmaceuticals, Inc. Derivados de indazol y aza-indazol sustituidos como moduladores de gamma-secretasa
NZ597505A (en) 2009-07-15 2013-05-31 Janssen Pharmaceuticals Inc Substituted triazole and imidazole derivatives as gamma secretase modulators
EP2518066B1 (en) * 2009-12-18 2016-05-18 Mitsubishi Tanabe Pharma Corporation Novel anti-platelet agent
US9145399B2 (en) 2010-01-15 2015-09-29 Janssen Pharmaceuticals, Inc. Substituted bicyclic triazole derivatives as gamma secretase modulators
ES2536442T3 (es) 2011-03-24 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados novedosos de triazolil piperazina y triazolil piperidina como moduladores de la gamma secretasa
JP6068464B2 (ja) 2011-07-15 2017-01-25 ヤンセン ファーマシューティカルズ，インコーポレーテッド γ−セクレターゼ調節剤としての新規な置換インドール誘導体
WO2013019682A1 (en) * 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
ES2585009T3 (es) 2012-05-16 2016-10-03 Janssen Pharmaceuticals, Inc. Derivados de 3,4-dihidro-2H-pirido[1,2-a]pirazina-1,6-diona sustituidos útiles para el tratamiento de (inter alia) enfermedad de Alzheimer
CA2889249C (en) 2012-12-20 2021-02-16 Francois Paul Bischoff Tricyclic 3,4-dihydro-2h-pyrido[1,2-a]pyrazine-1,6-dione derivatives as gamma secretase modulators
AU2014206834B2 (en) 2013-01-17 2017-06-22 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
CN103396405A (zh) * 2013-08-21 2013-11-20 中国药科大学 具有parp抑制作用的苯并咪唑-4-甲酰胺衍生物
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
WO2016018701A1 (en) * 2014-07-28 2016-02-04 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
HRP20220864T8 (en) * 2014-10-08 2023-02-03 Redx Pharma Plc N-pyridinyl acetamide derivatives as wnt signalling pathway inhibitors
CN105712937B (zh) * 2016-02-28 2019-02-22 河北宁格生物医药科技有限公司 一种治疗转移性肿瘤的化合物及其用途
CA3226162A1 (en) 2021-07-09 2023-01-12 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2641060A1 (de) * 1976-09-11 1978-03-16 Hoechst Ag Beta-lactamverbindungen und verfahren zu ihrer herstellung
JP2869561B2 (ja) * 1989-05-22 1999-03-10 大塚製薬株式会社 血小板粘着抑制剤
JPH06759B2 (ja) * 1989-09-22 1994-01-05 ファイザー製薬株式会社 新規なベンゾイミダゾール化合物
GB9225141D0 (en) * 1992-12-01 1993-01-20 Smithkline Beecham Corp Chemical compounds
DE4330959A1 (de) * 1993-09-09 1995-03-16 Schering Ag Neue Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
IL113472A0 (en) * 1994-04-29 1995-07-31 Lilly Co Eli Non-peptidyl tachykinin receptor antogonists
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
US6150379A (en) * 1997-11-26 2000-11-21 Axys Pharmaceuticals, Inc. Compounds and compositions as anticoagulants
US6344450B1 (en) * 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
AU5723500A (en) * 1999-05-24 2000-12-12 Cor Therapeutics, Inc. Inhibitors of factor xa
BR0012450B1 (pt) * 1999-06-23 2011-08-23 benzimidazóis substituìdos.
WO2001028993A2 (en) * 1999-10-19 2001-04-26 Merck & Co. Inc. Tyrosine kinase inhibitors
NZ524717A (en) 2000-09-11 2004-09-24 Chiron Corp Quinolinone derivatives
JP2004536113A (ja) 2001-07-03 2004-12-02 カイロン コーポレイション チロシンキナーゼおよびセリン／スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物
DE10139060A1 (de) * 2001-08-08 2003-02-20 Merck Patent Gmbh Phenylderivate

Also Published As

Publication number Publication date
RU2005108042A (ru) 2005-11-20
CN1674893A (zh) 2005-09-28
ATE386518T1 (de) 2008-03-15
EP1558247B1 (de) 2008-02-20
US20050272740A1 (en) 2005-12-08
AR041024A1 (es) 2005-04-27
ES2303606T3 (es) 2008-08-16
DE10238002A1 (de) 2004-03-04
DE50309217D1 (en) 2008-04-03
JP2006500369A (ja) 2006-01-05
BR0313634A (pt) 2005-06-21
CA2496139A1 (en) 2004-03-04
EP1558247A1 (de) 2005-08-03
JP4668614B2 (ja) 2011-04-13
WO2004017963A1 (de) 2004-03-04
US7566789B2 (en) 2009-07-28
AU2003250890A1 (en) 2004-03-11
CA2496139C (en) 2011-12-13

Similar Documents

Publication Publication Date Title
AU2003250890B2 (en) Benzimidazole derivatives
US20040038858A1 (en) Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours
US20040082563A1 (en) Phenyl derivatives 3
US20050203127A1 (en) 2-(Phenyl)-2h-pyrazole-3-carboxylic acid-n-4-(thioxo-heterocyclyl)-phenyl-amide derivatives and corresponding imino-heterocyclyl derivatives and relates compounds for use as inhibitors of the coagulation factors xa and/or viia for treating thromboses
US7199133B2 (en) Derivatives of phenoxy-n-′4-(isothiazolindin-1, 1-dioxid-2yl)phenyll-valerian-acid amide and other compounds as inhibitors of the coagulation factor xa in the treatment of thromboembolic diseases and tumors
CA2456717C (en) Phenyl derivatives as factor xa inhibitors
US20050176760A1 (en) N-'4-(2-imino-pyrrolidin-1-yl)phenyl!-acetamide and corresponding piperidine derivatives as factor xa inhibitors for the treatment of thrombo-embolic diseases
AU2004205354B2 (en) Carboxamide derivatives and their use as factor Xa inhibitors
CA2483228C (en) Carboxamides
SK1512003A3 (en) N-substituted-1-amino-1,1-dialkylcarboxylic acid derivatives
US20060135515A1 (en) Heterocyclic amides and their use treating thromboembolic diseases and tumors
EP1370522A1 (en) Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours
CA2528233A1 (en) Aroylsemicarbazide derivatives against thromboembolic diseases
MXPA04008479A (es) Derivados de semicarbazida.
KR20040018273A (ko) 탄수화물 유도체
AU2002249246A1 (en) Phenyl derivatives 3

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired